Hansoh Pharmaceutical Group's (HKG:3692) HS-20093 for injection obtained China's National Medical Products Administration's (NMPA) approval to be added as a breakthrough-therapy-designated drug for the treatment of patients with osteosarcoma, a type of bone cancer, a Tuesday bourse filing said.
The Chinese regulator approved the drug for the treatment of patients who have progressed on at least two prior lines of therapy.
HS-20093, also known as GSK5764227, is a B7-H3-targeted antibody-drug conjugate that is being developed in multiple clinical studies of small-cell lung cancer, head and neck cancers, and other solid tumors.
The injection has also been granted breakthrough therapy designation by NMPA previously for lung cancer and from the US Food and Drug Administration for the treatment of relapsed or refractory extensive-stage small-cell lung cancer, ES-SCLC.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。